Apnimed, Inc.
Apnimed, Inc.
- Market cap
- $669.84M
- P/E ratio
- 3.53
Your view on APMD
Overview
What the company does, where it operates, and who runs it.
About Apnimed, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kevin R. Lind
- Headquarters
- 39 John F. Kennedy Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kevin R. Lind
- Headquarters
- 39 John F. Kennedy Street, Cambridge, MA, US
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.
The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Apnimed, Inc.. Starting points for Apnimed, Inc.: P/E 3.5, EPS $5.95, beta 7.95 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Apnimed, Inc.. Trailing twelve-month EPS for Apnimed, Inc. stands at $5.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Targets, low to high
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.84 | −$1.16 | $0.51 | −$3.44 |
| Lowest estimate | −$0.84 | −$1.43 | −$0.06 | −$5.55 |
| Highest estimate | −$0.84 | −$0.88 | $1.07 | −$1.33 |
| Number of analysts | 1 | 2 | 1 | 3 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $99.37M | $22.44M |
| Lowest estimate | $0.00 | $0.00 | $82.41M | $13.80M |
| Highest estimate | $0.00 | $0.00 | $123.21M | $32.25M |
| Number of analysts | 0 | 0 | 2 | 4 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Apnimed, Inc.. Apnimed, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| INSPInspire Medical Systems, Inc. | Healthcare | Medical - Devices | $1.6B | ||
| NYXHNyxoah S.A. | Healthcare | Medical - Specialties | $82.0M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| VIRVir Biotechnology, Inc. | Healthcare | NASDAQ | $1.4B | ||
| VIVSVivoSim Labs, Inc. | Healthcare | NASDAQ | $4.3M | ||
| VKTXViking Therapeutics, Inc. | Healthcare | NASDAQ | $3.2B | ||
| VNDAVanda Pharmaceuticals Inc. | Healthcare | NASDAQ | $208.3M | ||
| VORVor Biopharma Inc. | Healthcare | NASDAQ | $1.0B | ||
| VPROViropro Inc. | Healthcare | OTC | $25,404 | ||
| VRAXVirax Biolabs Group Limited | Healthcare | NASDAQ | $446,402 | ||
| VRCAVerrica Pharmaceuticals Inc. | Healthcare | NASDAQ | $47.1M | ||
| VRCIVerde Science, Inc. | Healthcare | OTC | $239 | ||
| VRDNViridian Therapeutics, Inc. | Healthcare | NASDAQ | $3.4B | ||
| VRPXVirpax Pharmaceuticals, Inc. | Healthcare | NASDAQ | $26,093 | ||
| VRTXVertex Pharmaceuticals Incorporated | Healthcare | NASDAQ | $130.6B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| VTWOVanguard Russell 2000 ETF | $16.6B in assets | 0.01% | |
| IBRNiShares Neuroscience and Healthcare ETF | $9M in assets | 1.06% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.01% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.01% | |
| VTWVVanguard Russell 2000 Value ETF | $1.3B in assets | 0.01% | |
Largest holders first, then the funds most concentrated in APMD.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Apnimed, Inc. executives and directors. Shares of Apnimed, Inc. have traded between $16.12 and $29.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Apnimed, Inc.. Coverage tracks Apnimed, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Apnimed, Inc.